$305.10 Million in Sales Expected for R1 RCM Inc (NASDAQ:RCM) This Quarter

Equities analysts predict that R1 RCM Inc (NASDAQ:RCM) will announce $305.10 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for R1 RCM’s earnings, with estimates ranging from $304.70 million to $305.60 million. R1 RCM posted sales of $295.00 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.4%. The firm is expected to report its next quarterly earnings report on Tuesday, August 4th.

On average, analysts expect that R1 RCM will report full year sales of $1.20 billion for the current financial year, with estimates ranging from $1.16 billion to $1.25 billion. For the next year, analysts expect that the business will report sales of $1.43 billion, with estimates ranging from $1.33 billion to $1.54 billion. Zacks’ sales calculations are an average based on a survey of analysts that follow R1 RCM.

R1 RCM (NASDAQ:RCM) last released its quarterly earnings results on Tuesday, May 5th. The healthcare provider reported $0.05 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.03). R1 RCM had a net margin of 2.44% and a return on equity of 174.42%. The business had revenue of $320.50 million during the quarter, compared to analysts’ expectations of $318.76 million. During the same quarter last year, the company earned ($0.04) EPS. The firm’s revenue for the quarter was up 16.1% compared to the same quarter last year.

Several equities analysts have issued reports on RCM shares. Royal Bank of Canada started coverage on shares of R1 RCM in a research note on Monday, April 20th. They issued an “outperform” rating and a $12.00 price objective on the stock. SVB Leerink started coverage on shares of R1 RCM in a research note on Monday, April 13th. They issued a “market perform” rating and a $10.00 price objective on the stock. BidaskClub cut shares of R1 RCM from a “hold” rating to a “sell” rating in a research note on Saturday. ValuEngine raised shares of R1 RCM from a “hold” rating to a “buy” rating in a research note on Tuesday, March 17th. Finally, Zacks Investment Research cut shares of R1 RCM from a “hold” rating to a “sell” rating in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. R1 RCM presently has an average rating of “Hold” and a consensus price target of $13.43.

RCM stock traded down $0.17 on Friday, hitting $10.59. The company’s stock had a trading volume of 1,804,625 shares, compared to its average volume of 1,068,032. The firm has a 50 day moving average of $10.78 and a two-hundred day moving average of $11.35. R1 RCM has a 1 year low of $7.12 and a 1 year high of $13.99. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 14.63.

A number of large investors have recently added to or reduced their stakes in RCM. Copper Rock Capital Partners LLC purchased a new position in R1 RCM in the 1st quarter valued at about $749,397,000. Sunriver Management LLC lifted its holdings in shares of R1 RCM by 47.9% during the 1st quarter. Sunriver Management LLC now owns 3,348,550 shares of the healthcare provider’s stock worth $30,438,000 after acquiring an additional 1,085,100 shares during the period. Nuveen Asset Management LLC lifted its holdings in shares of R1 RCM by 62.9% during the 1st quarter. Nuveen Asset Management LLC now owns 1,170,457 shares of the healthcare provider’s stock worth $10,639,000 after acquiring an additional 451,861 shares during the period. Monarch Partners Asset Management LLC purchased a new position in shares of R1 RCM during the 1st quarter worth about $4,069,000. Finally, FMR LLC lifted its holdings in shares of R1 RCM by 20.4% during the 4th quarter. FMR LLC now owns 2,559,391 shares of the healthcare provider’s stock worth $33,220,000 after acquiring an additional 433,434 shares during the period. Institutional investors own 74.28% of the company’s stock.

R1 RCM Company Profile

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.

Featured Story: What are the qualifications of a portfolio manager?

Get a free copy of the Zacks research report on R1 RCM (RCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for R1 RCM (NASDAQ:RCM)

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.